Coronaviridae

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, February 6, 2024
C-reactive protein, Patent, Virus, COVID, Disorder, Vagus nerve, Patient, Blood, United States patent law, Coronaviridae, ElectroCore

ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).

Key Points: 
  • ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).
  • U.S. Patent No.
  • 11,894,148 entitled “Systems and Methods for Treating Patients With Diseases Associated With Viruses” generally relates to methods for treating disorders with viruses in the COVID family using electrical impulses transcutaneously to the vagus nerve for about 30 seconds to about 5 minutes, from 2 to 5 times per day, to reduce a level of C-reactive protein in the blood of the patient.

Guidelines for Organisations to Safely Navigate Extreme Heat During the Hajj Season from International SOS

Retrieved on: 
Wednesday, June 21, 2023
Destinations, Technology, Travel, Professional Services, Health, General Health, Business, Religion, Security, Consumer, Other Travel, Workforce, Congestion, Loss, Food, International, Drink, Miliaria, Heat, Face, King Abdulaziz International Airport, Dehydration, Heat cramps, Eye, Heat exhaustion, Head, Coronaviridae, Temperature, Caffeine, Vegetable, Heat stroke, MERS-related coronavirus, Social media, Mother, Thermoregulation, Humidity, Exertion, Grinnell Regional Medical Center, Animal, Cooking, Risk, Police, Water, International SOS, Bath, Heat syncope, JED, Meat, Rest, News, Skin, Safety, Swine acute diarrhea syndrome coronavirus, Tourism, Drug, Cosmetics, Hajj, Kingdom

As this year’s Hajj season occurs during the summer, pilgrims can expect to deal with the high summer temperatures and humidity.

Key Points: 
  • As this year’s Hajj season occurs during the summer, pilgrims can expect to deal with the high summer temperatures and humidity.
  • Therefore, International SOS recommends that organisations encourage their workforce to take the relevant precautions in order to have a safe and healthy Hajj.
  • To combat the challenges of extreme heat during the hot season, it is important for pilgrims to maintain proper hydration by drinking plenty of water.
  • Educate your employees about the symptoms of heat-related illnesses such as heat rash, heat cramps, heat syncope (heat collapse), heat exhaustion, and heat stroke.

AeroClean Technologies and Molekule Announce the Close of All-Stock Merger

Retrieved on: 
Thursday, January 12, 2023
Federal Food, Drug, and Cosmetic Act, Filter, Allergen, White House, COVID-19, Virus, B2B, Straits Air Freight Express, Coronaviridae, Severe acute respiratory syndrome coronavirus 2, American Rescue Plan Act of 2021, FDA, Korea Disease Control and Prevention Agency, Bacteria, CCO, Carbon, Mergers and acquisitions, Growth, PALM, ESG, RNA, Atmosphere, Research, HEPA, Filtration, ASHRAE, Atmosphere of Earth, Society, White, Acquisition, CDC, IAQ, Organic compound, PECO, Heating, ventilation, and air conditioning, Risk management, Molekule

Under the terms of the Merger, AeroClean stockholders now own approximately 50.5%, and Molekule stockholders own approximately 49.5%, of the outstanding shares of common stock of the combined company.

Key Points: 
  • Under the terms of the Merger, AeroClean stockholders now own approximately 50.5%, and Molekule stockholders own approximately 49.5%, of the outstanding shares of common stock of the combined company.
  • Effective at 9:00 a.m. eastern time on January 12, 2023, AeroClean changed its name and ticker symbol to Molekule Group, Inc. (Nasdaq: MKUL).
  • Molekule also recently began collaboration with key customers across the US who have deployed thousands of Molekule premium air purifiers throughout portions of their office spaces and enterprises.
  • The seven-member AeroClean Board of Directors will be expanded to eight members, with Brad Feld, Molekule board member and co-founder of venture capital firm Foundry, joining the combined company’s Board.

LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M 

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Ooredoo, PIA, HPV, B cell, University, Coronaviridae, Biomedical Research, Chlamydia, HIV, Public health, Vaccine Research Center, Government, Vaccine, VRI, Infection, Immune system, UPEC, IQT, Cancer, IMRB, University of Paris-Est Marne-la-Vallée

LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.

Key Points: 
  • LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • It is predicated on work by the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate.
  • Englehart, Director, IQT International Ltd UK: “We are impressed by LinKinVax’s team and its vision for developing world-class vaccine technology.
  • This new financing, completed in December 2022, includes a seed funding from private shareholders, beginning of 2022.

AeroClean’s Pūrgo™ Air Purifier Receives FDA Clearance for the Elimination of SARS-CoV-2

Retrieved on: 
Wednesday, December 7, 2022
PALM, RSV, RNA, Health, Bacteria, Food, FDA, Omicron, Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CDC, Indoor air quality, Fungus, Atmosphere, Coronaviridae, BEACH, Filtration, Severe acute respiratory syndrome coronavirus 2, Virus, COVID-19, HEPA, Vaccine, Heating, ventilation, and air conditioning

PALM BEACH GARDENS, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a leading air hygiene technology company, today announced that, the U.S. Food and Drug Administration (“FDA”) has granted AeroClean 510k clearance (K223328) to update its Pūrgo™ air purifier’s (“Pūrgo™”) indications for use to include the elimination of SARS-CoV-2, the RNA virus that causes COVID-19. The FDA has reviewed the laboratory performance data and confirmed the applicability of Pūrgo to remove SARS-CoV-2 from the air in indoor environments. The clearance adds SARS-CoV-2 to the list of microorganisms already cleared. As part of AeroClean’s ongoing commitment to improve Indoor Air Quality (“IAQ”) for a healthier and safer world, the Company has commenced additional efficacy testing on viruses that are known threats to health such as influenza and respiratory syncytial virus (RSV).

Key Points: 
  • The FDA has reviewed the laboratory performance data and confirmed the applicability of Pūrgo to remove SARS-CoV-2 from the air in indoor environments.
  • “Our team is dedicated to improving indoor air quality through the creation of long-term, health-focused solutions, and this latest indication validates the significant strength of our Pūrgo™ air sanitization device.
  • AeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—by improving indoor air quality.
  • Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops.

Senstar Technologies Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, September 22, 2022
Income, Mission statement, Coronaviridae, GAAP, ID, EBITDA, Contract, Company, COVID19, SNT, Federal aid during the COVID-19 pandemic in Canada, U.S. Securities and Exchange Commission, Program, Travel, Solution, Annual report, EMEA, NASDAQ, Security (finance), Time in the United Kingdom, APAC, Time, Renewable energy, Video game, Bank

Revenue for the second quarter of 2022 was $9.1 million, a decrease of 9.7% compared with $10.1 million in the second quarter of 2021.

Key Points: 
  • Revenue for the second quarter of 2022 was $9.1 million, a decrease of 9.7% compared with $10.1 million in the second quarter of 2021.
  • Operating expenses for the second quarter of 2022 were $5.4 million, an increase of 11.2% compared to the prior year's second quarter operating expenses of $4.8 million.
  • Operating income was $0.1 million for the second quarter of 2022 compared to $2.2 million in the second quarter of 2021.
  • EBITDA from continuing operations for the second quarter was $0.5 million versus $2.5 million for the second quarter of 2021.

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Retrieved on: 
Tuesday, September 13, 2022
Regulation, PRDS, Investor, Tablet, Safety, Infection, COVID-19, Risk, Severe acute respiratory syndrome coronavirus 2, Intention, Population, Private Securities Litigation Reform Act, Toxicology, Forward-looking statement, Patient, Clinical trial, U.S. Securities and Exchange Commission, Annual report, Nasdaq, Regulation Fair Disclosure, Food, NCT, Death, Coronaviridae, Security (finance), GLOBE, SEC, Mpro, Disclosure, Pharmaceutical industry, Pardes

CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today reported commencement of a Phase 2 double-blind, randomized study to evaluate the antiviral activity, safety, and efficacy of orally administered PBI-0451 compared with placebo in non-hospitalized symptomatic adults with COVID-19 who are not at increased risk of progressing to severe illness.  

Key Points: 
  • Pardes Biosciences expects to enroll 210 patients in the Phase 2 clinical trial at approximately 75 sites within the United States.
  • We look forward to evaluating PBI-0451 in this broad patient population and sharing preliminary results in the first quarter of 2023.
  • PBI-0451 is a potential stand-alone, novel, direct-acting oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections in Phase 2 clinical development.
  • Accordingly, investors should monitor Pardes Biosciences Investors website, in addition to following Pardes Biosciences press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts.

Global In Vitro Diagnostic eCommerce Market Analysis Report 2022 - R&D eCommerce Marketplace Opens Opportunities and Optimizes Cost and Time for Researchers and Scientists

Retrieved on: 
Monday, August 22, 2022
Machine learning, COVID-19, Engineering, University, POCT, Technology, EDI, Government, Vaccine, Health, Coronavirus, United States Secretary of Commerce, Coronaviridae, IVD, Laboratory, Lancet, Hospital, Leadership, E-commerce, Internet, Communication, Efficiency, Personal protective equipment, Diagnosis, Gaps, Industry, Environment, Patient, Medical device, Online shopping, Healthcare

DUBLIN, Aug. 22, 2022 /PRNewswire/ --The "In Vitro Diagnostic eCommerce Business Models Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 22, 2022 /PRNewswire/ --The "In Vitro Diagnostic eCommerce Business Models Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This study assesses the eCommerce business potential across sectors, creating resilient healthcare and diagnostic market opportunities for R&D, manufacturing, and supply chain functions.
  • The IVD market is buoyant due to the soaring demand for products, molecular diagnostics, immunoassays, and POCT in chronic diseases.
  • The study also examines the competitive environment, strategies, market models, and use cases for success in the IVD eCommerce platform industry.

Outlook on the Isolator Box Glove Global Market to 2027 - Technological Advancement is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 19, 2022
Research, Science, COVID-19 vaccine, Glass, Technology, Growth, Plastic, Geography, COVID, Clinical trial, Stainless steel, National Institute, Infection, Research, NIAID, Coronaviridae, National Institute of Allergy and Infectious Diseases, Government, Hypalon, COVID-19, Polymer, Vaccine, CSM, Drug development, CAGR, Isolator, HIV, Beauty salon, Pharmaceutical industry, Neoprene, Latex

The isolator box glove market is estimated to grow at a CAGR of 7.68% over the forecast period for 2022-2027.

Key Points: 
  • The isolator box glove market is estimated to grow at a CAGR of 7.68% over the forecast period for 2022-2027.
  • The demand for isolator box gloves will grow with rising investment in research and development in healthcare, energy, power and chemical fields.
  • One of the prime reasons supporting the growth of the isolator box glove market is the technological advancement in isolator box gloves.
  • The COVID -19 pandemic has positively impacted the growth of the isolator box glove market.

2022 In Vitro Diagnostic eCommerce Business Models Growth Opportunities Report: Disruptive Differentiation in Supply Chain Management Drives New Growth Potential - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Medical Devices, Health, Machine learning, Laboratory, Industry, POCT, Coronaviridae, Technology, Leadership, Diagnosis, Hospital, United States Secretary of Commerce, Environment, Communication, Government, Patient, E-commerce, Personal protective equipment, COVID-19, Vaccine, Coronavirus, Gaps, Engineering, IVD, Health, University, Lancet, EDI, Internet, Efficiency, Medical device, Online shopping, Healthcare

The "In Vitro Diagnostic eCommerce Business Models Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Diagnostic eCommerce Business Models Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This study assesses the eCommerce business potential across sectors, creating resilient healthcare and diagnostic market opportunities for R&D, manufacturing, and supply chain functions.
  • It explores other scalable, cost-efficient business opportunities with new B2B products, customized outsourcing services, and technology-enabled tools for efficiency and ease of operations.
  • The study also examines the competitive environment, strategies, market models, and use cases for success in the IVD eCommerce platform industry.